Showing chemical card for Rindopepimut (CFc000323650)
| Record Information | |
|---|---|
| Version | 1.0 |
| Creation Date | 2022-09-06 19:45:53 UTC |
| Update Date | 2022-09-14 04:54:45 UTC |
| Chemfont ID | CFc000323650 |
| Molecule Identification | |
| Common Name | Rindopepimut |
| Definition | Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH). The US FDA granted it Breakthrough Therapy Designation for glioblastoma in Feb 2015. |
| Structure |  |
| Synonyms | Not Available |
| Chemical Formula | |
| Average Molecular Weight | |
| Monoisotopic Molecular Weight | |
| IUPAC Name | |
| Traditional Name | |
| CAS Registry Number | 1108208-65-6 |
| SMILES | Not Available |
| InChI Identifier | |
| InChI Key | |
| Chemical Taxonomy | |
| Classification | Not classified |
| Functional Ontology | |
| Physiological effect | Not Available |
| Disposition | |
| Process | Not Available |
| Role | Not Available |
| Physical Properties | |
| Predicted Properties | Not Available |
| External Links | |
| External Links | Not Available |
| References | |
| Synthesis Reference | Not Available |